GLP-3 30MG

•  For Research Use Only

🧪 Compound Overview

• Type: Investigational peptide-based drug candidate

• Mechanism: Retatrutide is a multi-receptor agonist targeting GLP-1, GIP, and glucagon receptors, under clinical development for metabolic diseases such as obesity and type 2 diabetes.

• Status: Currently in clinical trials; not FDA-approved for general medical use.

⚙️ Research Applications

• Investigated for effects on weight loss, glycemic control, and metabolic improvements.

• Used exclusively in clinical research and experimental studies.

• No approved dosing or administration guidelines outside trial settings.

⚠️ Regulatory & Safety Information

• Retatrutide is not approved by the FDA for routine clinical or veterinary use.

• Provided only for clinical research and investigational purposes under appropriate regulatory oversight.